Catalyst Wire Dossier Catalyst Wire Dossier

CAL-101 (idelalisib)

idelalisib · Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAL-101 (idelalisib), covering 2024-05-09 to 2024-05-09. Get the full timeline:

Most recent: Clinical Trial Update: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) [Phase 2]

See pricing